Avenzo Therapeutics secures $60m in series B funding for oncology therapies

Avenzo’s lead drug candidate, AVZO-021, is a novel CDK2 inhibitor undergoing a Phase I trial for advanced solid tumours and HR+/HER2- metastatic breast cancer. Photo by: swiftsciencewriting/Pixabay.